HIPEC in T4a colon cancer: A defendable treatment to improve oncologic outcome?

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3123-3129

  Hompes, D ^a   Tiek, J ^a   Wolthuis, A ^a   Fieuws, S ^a   Penninckx, F ^a   Van Cutsem, E ^b   D'Hoore, A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KU LEUVEN   (Belgium)

Author keywords

Adjuvant; Colon cancer; HIPEC; Oncologic outcome; T4a

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTHERMIA AND INTRAPERITONEAL CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLONIC NEOPLASMS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; PERITONEUM; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84869794824     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds173     Document Type: Article

References (45)

1. Shepherd N, Baxter K, Love S et al. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997; 112: 1096-1102.
2. Ludeman L, Shepherd N et al. Serosal involvement in gastrointestinal cancer: its assessment and significance. Histopathology 2005; 47: 123-131.
3. Shepherd N, Baxter K, Love S et al. Influence of local peritoneal involvement on pelvic recurrence and prognosis in rectal cancer. J Clin Pathol 1995; 48: 849-855.
4. Petersen V, Baxter K, Shepherd N et al. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51: 65-69.
5. Newland RC, Chapuis PH et al. Peritoneal involvement by rectal cancer. J Clin Pathol 1996; 49: 694-695.
6. Park Y, Park K, Park J et al. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg 1999; 23: 721-726.
7. Williams GT et al. A long hard look at Dukes' B: identification of prognostic pathological factors in Dukes' B colon cancer. Gut 2002; 51: 6-7.
8. Edge S, Byrd D, Compton C et al. AJCC Cancer Staging Manual (7th Edition. Eds.) 2010, ISBN 978-0-387-88440-0.
9. Pintilie M. Competing Risks: A Practical Perspective. Chichester: Wiley 2006.
10. Therneau TM, Grambsch PM et al. Modeling survival data: extending the Cox model. New York, NY: Springer-verlag 2000.
11. Schemper M, Smith T. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
12. Jayne D, Fook S, Seow-Choen F et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550.
13. Folprecht G, Köhne C, Lutz M et al. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Cancer Treat Res 2007; 134: 425-440.
14. Chu D, Lang N, Thompson C et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: 364-367.
15. Sadeghi B, Arvieux C, Gilly F et al. Peritoneal carcinomatosis from nongynecologic malignancies. Results of the EVOCAPE I multicentric prospective study. Cancer 2000; 88: 358-363.
16. Hompes D, Boot H, Verwaal V et al. Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience. J Surg Oncol 2011; 104: 269-273.
17. Verwaal VJ, Zoetmulder FAN et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71.
18. Koppe MJ, Bleichrodt RP et al. Peritoneal carcinomatosis of colorectal origin: incidence and treatment strategies. Ann Surg 2006; 243: 212-222.
19. Shen P, Levine E, Hall J et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138: 26-33.
20. Sugarbaker PH et al. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg 1999; 384: 576-587.
21. Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
22. Elias D, Glehen O, Pocard M et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel and nonpseudomyxoma appendix. Ann Surg 2010; 251: 896-901.
23. Verwaal V, Bruijn S, Boot H et al. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432.
24. Maggiori L, Elias D et al. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 2010; 36: 599-603.
25. Rekhraj S, Aziz O, Prabhudesai S et al. Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer: a meta-analysis. Ann Surg Oncol 2007; 15: 60-68.
26. Noura S, Ohue M, Seki Y et al. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum 2009; 52: 1312-1320.
27. Noura S, Ohue M, Shingai T et al. Effects of intraperitoneal chemotherapy with Mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol 2010; 18: 396-404.
28. Nishikawa T, Watanabe T, Sunami E et al. Prognostic value of peritoneal cytology and the combination of peritoneal cytology and peritoneal dissemination in colorectal cancer. Dis Colon Rectum 2009; 52: 2016-2021.
29. Fujii S, Shimada H, Yamagishi S et al. Evaluation of intraperitoneal lavage cytology before colorectal cancer resection. Int J Colorectal Dis 2009; 24: 907-914.
30. Katoh H, Yamashita K, Sato T et al. Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer. Br J Surg 2009; 96: 769-777.
31. Baskaranathan S, Philips J, McCredden P et al. Free colorectal cancer cells on the peritoneal surface: correlation with pathologic variables and survival. Dis Colon Rectum 2004; 47: 2076-2079.
32. Hase K, Ueno H, Kuranaga N et al. Intraperitoneal exfoliated cancer cells in patients with colorectal cancer. Dis Colon Rectum 1998; 41: 1134-1140.
33. Bosch B, Guller U, Schnider A et al. Perioperative detection of disseminated cells is an independent prognostic risk factor in patients with colorectal cancer. Br J Surg 2003; 90: 882-888.
34. Guller U, Zajac P, Schnider A et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-775.
35. Hara M, Nakanishi H, Jun Q et al. Comparative analysis of intraperitoneal minimal free cancer cells between colorectal and gastric patients: using quantitative RT-PCR: possible reason for rare peritoneal recurrence in colorectal cancer. Clin Exp Metastasis 2007; 24: 179-189.
36. Elias D, Bonnay M, Puizillou J et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002; 13: 267-272.
37. Verwaal V, van Tinteren H, van Ruth S et al. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85: 61-67.
38. Van Ruth S, Mathôt R, Verwaal V et al. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet 2004; 43: 131-143.
39. Lambert L, Armstrong T, Lee J et al. Incidence, risk factors and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 2009; 16: 2181-2187.
40. Elias D, Goere D, Blot F et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after complete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol 2007; 14: 1818-1824.
41. van Leeuwen B, Graf W, Pahlman L et al. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 2008; 15: 745-753.
42. Elias D, Gilly F, Boutitie F et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68.
43. Elias D, Sideris L et al. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003; 12: 755-769.
44. Elias D, Goere D, Di Pietrantonio D et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008; 247: 445-450.
45. Elias D, Honoré C, Dumont F et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011; 254: 289-293.